3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
20
Active not recruiting
5
Withdrawn
1
Terminated
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
33
Carboplatin
18
Cisplatin
15
Nivolumab
14
Pemetrexed
12
Paclitaxel
12
Ipilimumab
11
atezolizumab
10
Gemcitabine
10
venetoclax
9
Radiotherapy
9
Docetaxel
9
durvalumab
8
Cyclophosphamide
8
fludarabine
7
Specimen Handling
7
Biopsy
7
Bevacizumab
7
tislelizumab
6
enzalutamide
6
Trastuzumab
6
Practice Guidelines as Topic
6
Cetuximab
6
tazemetostat
5
fludarabine phosphate
5
Surveys and Questionnaires
5
Standard of Care
5
Radiosurgery
5
Magnetic Resonance Spectroscopy
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
enfortumab vedotin
×
90 days
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA